Twitter: @jockinmikeg
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DAIO: great post, and thanks for breaking down the math. I have been buying anything under $8 and consider it a bargain.
DAIO like this one for a long term hold. Started a position in the $7.80s, and have no plans to sell until double digits. Nice post.
CYBE thanks for your reply. I am playing the oversold bounce and buying shares in the $15.70 area. Price action will determine if it's worth a hold into Q3. I feel good buying anything under $16. This stock was trading in the $40s just 6 months ago, so momo crowds have been known to jump on it. They had news today, but it didn't do anything for the share price.
Back in SINO @ 2.90 for a starter. Adding. What's your opinion on earnings this upcoming Q?
No volume today after ER release scheduled. If numbers are supposed to be great, surprised no one is buying. Or is everyone here in at a lower price and just holding?
In DAIO avg 7.87 looking to add on weakness. Doesn't make sense why it dropped so much after stellar ER
Added today, doubling my position. Avg .59 great value here
CYBE: do you think it's a buy here in the $17's? Looks like shorts piled onto a bad ER and drove it down hard. What's to like here, in your opinion, if anything, going into Q3-4?
CAPC: joined you for a starter Friday. In 2k shares looking to add. Undervalued indeed
In Friday for a starter .5802 looking to add. Solid medium to LT play.
Most definitely. The market has priced XCede in as a failure because it's a cash burn and hasn't done much for years. If or when it gets some credible data released, I think it will go higher. Someone bought a lot of shares Monday.
Chart looks like it wants to fill that gap above .90 - break .76 and it goes
Looks like an institutional buy this morning. This thing is just simmering before XCede preclinical news.
CRTN link back for chart, ready to breakout. Looking to fill gap above .88
Great move today on heavy volume for this low floater. Anyone on this? This is going back above $1 imo
CRTN big volume pop. Accumulation happening here.
CRTN moving on volume.
CRTN link back nice move today, heading into that gap with some volume. Another gap above .89, could be an explosive move.
This report suggests stock is undervalued fundamentally
http://mportal.geoinvesting.com/geoarticles/1276/this_company_trades_at_liquidation_value_but_don_t_count_out_substantial_upside
CRTN holding support heading into gap area above .60 into the 50ma. Trading 1.5x cash, under liquidation value ($.61), Low float, proj higher revenues Q2 and back half of year. Beatable comp Q2, potential buyout target, known for explosive moves.
http://stockcharts.com/h-sc/ui?s=CRTN&p=D&b=5&g=0&id=p47619368391
CRTN link back, 13ema bullish cross @ .51 heading into that gap above .60. Low floater beat down stock trading 1.5x cash, below liquidation value.
CRTN: This Company Trades at Liquidation Value but don't Count Out Substantial Upside
http://mportal.geoinvesting.com/geoarticles/1276/this_company_trades_at_liquidation_value_but_don_t_count_out_substantial_upside
Suggests anything under $.61 is cheap
Chart looks ready, w/1st close above 8ema since 3/30 gap drop. Pincher chart starting to open up.
http://stockcharts.com/h-sc/ui?s=CRTN&p=D&b=5&g=0&id=p09862571269
CRTN, agree with you that there is not explosive volume yet, but it's low float so it doesn't take much. I was just saying I like the setup
CRTN approaching 10-day high volume and the stock is up as the chart is starting to show positive divergences
CRTN on radar for big move. Pincher chart opening up w/1st close above 8 ema since 3/30. Blew thru 13ema .51 new support. 50dma .72. Trading near cash, under liquidation value ($.61), 3.9m float, easy Q2 comp, known for explosive moves
http://stockcharts.com/h-sc/ui?s=CRTN&p=D&b=5&g=0&id=p47619368391
Long term play for sure, but XCede may bear fruit near-to mid term with positive preclinical data, which may spark some attention after weighing on the books dormant for so long.
CRTN on radar for big move. Pincher chart opening up w/1st close above 8 ema since 3/30. Blew thru 13ema .51 new support. Trading near cash, under liquidation value ($.61), 3.9m float, easy Q2 comp, known for explosive moves
CRTN pincher about to move: http://stockcharts.com/h-sc/ui?s=CRTN&p=D&b=5&g=0&id=p10658858032
CRTN: This Company Trades at Liquidation Value but don't Count Out Substantial Upside
http://mportal.geoinvesting.com/geoarticles/1276/this_company_trades_at_liquidation_value_but_don_t_count_out_substantial_upside
Suggests anything under $.61 is cheap
Trading under liquidation value and near cash. Any downside is limited here, and they have an easy comp Q2. Also the company is a cheap buyout target at just over $4M and a good balance sheet with no poison pill. Insiders have bought and may continue.
I have been adding too. Positive preclinical trial news for XCede and I think this gets some attention, as it almost feels like failure is priced in since it sat on the shelf so long. They have credible partners for the biomedical and we should be hearing results this year. They have done a good job reducing debt, but revenues are lumpy. Optometrics growth should add a few cents per share over the next couple years.
Thanks, it's trading right near cash so I'm in for value but the chart looks like a pincher
What do you think of CRTN as a pincher play? TIA
Dynasil Corp Schedules Fiscal 2017 Second Quarter Financial Results Conference Call:
http://www.prnewswire.com/news-releases/dynasil-corporation-schedules-fiscal-2017-second-quarter-financial-results-conference-call-300452311.html
CLCT ($24.87): reported record results for 3rd quarter and 9 months ended 3/31/07.
http://www.globenewswire.com/news-release/2017/05/03/978169/0/en/Collectors-Universe-Reports-Record-Operating-Results-for-Third-Quarter-and-Nine-Months-ended-March-31-2017.html
Shares falling on earnings. Company does authentication services and grading for coins, trading cards, autographs, tickets, etc. Collectors Universe, Inc. is considered the leader in the industry of third-party grading and authentication services for high-value collectibles. Their PSA-graded trading cards command the highest premiums at auction houses, often as high as 25%. But most of their revenue comes from their domination of the graded coin market (PCGS), and they have significant business overseas in China.
They do own the lions' share market in the industry... Made .35 this Q and paid out a divvy; I think the ex-div date is looming in Mid-May. Yet they've experienced nice growth year over year, which may indicate more dealers and investors are seeking PCGS/PSA/DNA services to certify their investment grade collectibles. Earnings I'm sure are volatile and fueled by discretionary income, metals prices, economy strength, etc. but might be worth a look.
Low O/S and solid insitutional interest. Directors have sold some shares on the run-up recently, so that's something to be wary of. I have no position, but interested. Do your own DD
SINO: agree and why I bought this as a position trade, though people are having fun day and swing trading it. This one should be good for at least a few quarters.
DYSL some volume. Incredible how thin this is. There aren't many shares available.
SPCL: that's a lot of shares. Hope those don't hit the market.
After much cost averaging, on the right side of the trade and holding because I think the contracts research and optics are growing and I still don't think much value is assigned to biomedical in the stock price. Any positive XCede trial news and this breaks out to new 52-wk highs. We have 2 reputable investors/partners in Mayo Clinic and Cook who know a whole lot more about XCede than we do and they apparently like the numbers. Last contact w/co., was told the Xcede trial is "on schedule" for dosing patients this year. 3 of 9 required toxicology studies are underway along with QC details and other necessary steps by Cook Biotech. They are happy with their progress. So am I, after Xcede sitting on the shelf so long; it's progress. IMO the lack of progress til now is why the market up to this point has seen XCede as dead money. Any clinical progress with it will increase investor interest and add value to that subsidiary.
Some complain they are not shareholder-friendly, but my emails always were answered.
Lack of investor awareness, past performance including the drag of XCede, may be contributing factors. Also some have stated that management doesn't seem to be able to sell the story to Wall Street.
On that note, I think investor sentiment is turning around some. We got a partner for XCede to start the pre-clinicals, so positive progress will add value to biomedical and imo share price. Optics is growing. and current administration looks to be interested in increasing defense spending, which is good for RMD. Also, one of Sulick's CC responses seemed to allude that the major holders may be open to selling parts of the company since they own almost half of DYSL and are getting old. He said the board would meet in May, so who knows we may see a buyout or partial asset sale down the road.
$750k NASA Contract, 4/12:
https://www.usaspending.gov/transparency/Pages/TransactionDetails.aspx?RecordID=0E013B25-DCDC-494F-A0EE-46E4497EC457&AwardID=56763681&AwardType=C
$500k DHS Contract, 3/31:
https://www.usaspending.gov/transparency/Pages/TransactionDetails.aspx?RecordID=421459A4-2420-4514-B353-EBB59CAA206A&AwardID=51639214&AwardType=C